Vimarsana
Biggest News Aggregation in the World

Page 12 - Tom Mchugh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tom Mchugh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tom Mchugh Today - Breaking & Trending Today

Middlesex-London adds 114 COVID-19 cases, revises record number down - Vimarsana News

Middlesex-London adds 114 COVID-19 cases, revises record number down

The Middlesex-London Health Unit (MLHU) is reporting 114 new COVID-19 cases Wednesday and two new deaths, while also revising Tuesday’s record-setting 184 cases down to 161.

Unemployment System Audited After Pandemic Failures - Vimarsana News

Unemployment System Audited After Pandemic Failures

Massive delays in claims, duplicate payments and an unreliable call center among issues found in report. //end headline wrapper ?> Get a daily rundown of the top stories on Urban Milwaukee Amy Pechacek, transition director at the Wisconsin Department of Workforce Development, testifies Wednesday before the Joint Legislative Audit Committee. Wisconsin Eye screen capture. Tens of thousands of people who have been waiting on their unemployment insurance claims may learn by the end of the year whether they will get paid and start receiving funds, the acting head of the state’s labor department...

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA - Vimarsana News

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA

Share: DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. "The submission of our NDA represents a significant milestone for the Company. We look forward to working with the FDA during the NDA review process in order to get once-nightly FT218 approved and commercially available to ...